伦巴第地区EQA质控品在酶类、钙和肌酐检测中的互通性评估
该多中心横断面研究评估了伦巴第地区EQA项目中三种冻干人血清质控品在八项临床化学检测物上的互通性,采用IFCC差值偏差框架进行312次方法两两比较。结果显示互通性因检测物和方法而异,同一厂商内比较通常支持互通性,而跨厂商比较常显示非互通性,仅少数配对(如ALP的Abbott-Siemens、酶法肌酐的Roche-Werfen)显示完全互通。
要点
- 同一厂商内方法比较通常支持质控品互通性,跨厂商比较常显示非互通性。
- 仅少数方法配对显示完全互通,如ALP的Abbott-Siemens和酶法肌酐的Roche-Werfen。
- 特定基质-方法相互作用(如CHE干片系统、钙NM-BAPTA与 arsenazo III)导致系统性非互通。
核心结论
- 这些质控品的互通性高度可变且依赖于检测物,限制了跨方法准确性评估的解释。
- EQA设计需严格验证互通性以支持方法间偏倚评估和标准化。
研究设计与样本
- 多中心横断面研究,覆盖十家临床实验室。
- 评估三种冻干人血清质控品(补充非人酶和无机/有机成分),六次重复分析,以及十五份人血清混合样本三次重复分析。
- 纳入八项检测物:碱性磷酸酶(ALP)、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、肌酸激酶、乳酸脱氢酶、胆碱酯酶(CHE)、肌酐和钙。
主要发现
- 互通性模式因检测物和方法而异。
- 同一厂商内比较通常支持互通性,跨厂商比较常显示非互通性,偶见水平依赖行为。
- 完全互通仅见于少数配对,如ALP的Abbott-Siemens、酶法肌酐的Roche-Werfen。
- 特定基质-方法相互作用(如CHE干片系统、钙NM-BAPTA与 arsenazo III)导致系统性非互通。
关键数值与推荐
- 采用IFCC差值偏差框架进行312次方法两两比较。
- 接受限预定义为0.5倍允许总误差,主要源自EFLM生物学变异数据库。
临床怎么用
- 在跨方法准确性评估中需考虑质控品互通性限制。
- EQA设计应严格验证互通性以支持方法间偏倚评估和标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: External Quality Assessment (EQA) is essential for ensuring inter-laboratory comparability, yet the interpretability of EQA data depends critically on the commutability of control materials (CM). This study assessed the commutability of CM used in the Lombardy Regional EQA program for selected clinical chemistry measurands. METHODS: A multicenter cross-sectional study across ten clinical laboratories, evaluated the commutability of three lyophilized human serum control materials supplemented with non-human enzymes and inorganic/organic constituents, analyzed in six replicates, and fifteen human serum pools analyzed in triplicate. Eight measurands were included: alkaline phosphatase (ALP), alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, cholinesterase (CHE), creatinine, and calcium. Commutability was evaluated pairwise among 312 method comparisons using the IFCC "difference-in-bias" framework. Acceptance limits were predefined as 0.5 × allowable total error, derived primarily from the EFLM Biological Variation database. RESULTS: Patterns of commutability varied markedly across measurands and methods. Within-vendor comparisons generally supported commutability, whereas cross-manufacturer comparisons frequently demonstrated non-commutability, with isolated cases of level-dependent behavior. Full commutability across all CM was observed only in selected pairings (e.g., Abbott-Siemens for ALP; Roche-Werfen for enzymatic creatinine). Specific matrix-method interactions (e.g., dry-slide systems for CHE; NM-BAPTA versus arsenazo III for calcium) accounted for systematic non-commutability. CONCLUSIONS: The study confirms that commutability of these CM is highly variable and measurand-dependent, limiting the interpretation of accuracy assessments in many cross-method settings. These findings underscore the need for rigorous verification of commutability in EQA design to support meaningful assessment of inter-method bias and harmonization.
引用
- Carobene A, Vidali M, Ceriotti F, et al. Evaluation of the commutability of lombardy region EQA control materials for enzymes, calcium, and creatinine. Clin Chim Acta. 2025. PMID: 41308721. doi:10.1016/j.cca.2025.120745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。